Evidence map›Paper›PMID 36287952›Full record

ArticleToxins2022

Construction, Characterization, and Application of a Nonpathogenic Virus-like Model for SARS-CoV-2 Nucleocapsid Protein by Phage Display.

Yuting Wu, Bing Liu, Zhiwei Liu, Pengjie Zhang, Xihui Mu, Zhaoyang Tong

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuting WuState Key Laboratory of NBC Protection for Civilian, Beijing 102205, China.ORCID 0000-0002-7720-8024
Bing LiuState Key Laboratory of NBC Protection for Civilian, Beijing 102205, China.
Zhiwei LiuState Key Laboratory of NBC Protection for Civilian, Beijing 102205, China.
Pengjie ZhangState Key Laboratory of NBC Protection for Civilian, Beijing 102205, China.
Xihui MuState Key Laboratory of NBC Protection for Civilian, Beijing 102205, China.
Zhaoyang TongState Key Laboratory of NBC Protection for Civilian, Beijing 102205, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the outbreak and spread of COVID-19, a deep investigation of SARS-CoV-2 is urgent. Direct usage of this virus for scientific research could provide reliable results and authenticity. However, it is strictly constrained and unrealistic due to its high pathogenicity and infectiousness. Considering its biosafety, different systems and technologies have been employed in immunology and biomedical studies. In this study, phage display technology was used to construct a nonpathogenic model for COVID-19 research. The nucleocapsid protein of SARS-CoV-2 was fused with the M13 phage capsid p3 protein and expressed on the M13 phages. After validation of its successful expression, its potential as the standard for qPCR quantification and affinity with antibodies were confirmed, which may show the possibility of using this nonpathogenic bacteriophage to replace the pathogenic virus in scientific research concerning SARS-CoV-2. In addition, the model was used to develop a system for the classification and identification of different samples using ATR-FTIR, which may provide an idea for the development and evaluation of virus monitoring equipment in the future.

Indexed as

COVID-19VirusesBacteriophage M13Capsid ProteinsCell Surface Display TechniquesHumansNucleocapsid ProteinsSARS-CoV-2Capsid ProteinsNucleocapsid ProteinsM13 phagenucleocapsid proteinp3 proteinphage displaySARS-CoV-2

Identifiers

PMID36287952
PMCPMC9607219
OpenAlexW4304187094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.